Therapy Directory

Talquetamab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Talquetamab as a study intervention. Browse Talquetamab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Multiple Myeloma
Interventions: Teclistamab, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 67
States / cities: Gilbert, Arizona • Tucson, Arizona • Clovis, California + 53 more

Conditions: Multiple Myeloma in Relapse
Interventions: Talquetamab, Daratumumab; Drug
Lead sponsor: Larysa Sanchez; Other
Eligibility: 70 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma (MM)
Interventions: teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy; Drug · Procedure
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Multiple Myeloma, Post Stem Cell Transplant
Interventions: Talquetamab, Talquetamab and Lenalidomide; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Multiple Myeloma
Interventions: Sirolimus, Teclistamab, Talquetamb; Drug · Biological
Lead sponsor: Christopher Strouse; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Multiple Myeloma
Interventions: Talquetamab, Teclistamab; Drug
Lead sponsor: Noffar Bar; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: New Haven, Connecticut • Rochester, New York

Conditions: Multiple Myeloma
Interventions: Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 17
States / cities: Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more

Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
Interventions: Talquetamab, Mezigdomide, Dexamethasone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions: Talquetamab, Iberdomide, Dexamethasone, Bone Marrow Biopsy; Biological · Drug · Procedure
Lead sponsor: Alfred Chung, MD; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Myeloma
Interventions: Talquetamab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Multiple Myeloma
Interventions: bb2121, Lenalomide, Talquetamab; Biological · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 18
States / cities: Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 12 more

Conditions: Multiple Myeloma
Interventions: Teclistamab, Talquetamab, Daratumumab SC; Drug
Lead sponsor: Carl Ola Landgren, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Miami, Florida

About this Talquetamab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Talquetamab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Talquetamab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Talquetamab clinical trials

Filter and sort this therapy

Live official records

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

About this Talquetamab clinical trials directory page